Glenmark gets tentative nod from USFDA for Fingolimod capsules
New Delhi : Drug firm Glenmark Pharmaceuticals USA said it has got tentative approval from the United States Food and Drug Administration (USFDA) for Fingolimod capsules.
These capsules are used in the treatment of adult patients with relapsing forms of multiple sclerosis.
"Glenmark Pharmaceuticals USA has been granted tentative approval by the USFDA for Fingolimod capsules, 0.5 mg, the generic version of Gilenya capsules of Novartis Pharmaceuticals Corp," Glenmark said in a BSE filing.
As per IMS Health sales data for the 12 month period ended January 2017, Gilenya capsules 0.5 mg had annual sales of approximately USD 2.03 billion, it added.
Shares of Glenmark Pharmaceuticals were trading 0.78 per cent down at Rs 879.45 apiece on BSE.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd